 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Acceleron Pharma
XLRN
Acceleron Pharma has been acquired by Merck (MRK)
Acceleron: Neutral On Stock Price Gains [April 5, 2021, Seeking Alpha]
Acceleron Reblozyl For Beta Thalassemia Is Just The Beginning [March 4, 2020, Seeking Alpha]
Acceleron Heads To Commercial Success [December 2, 2019, Seeking Alpha]
FDA Approves Reblozyl (Luspatercept) for Beta Thalassemia [November 8, 2019, Celgene Press Release]
Analyst Conference Notes by William P. Meyers |
|||
| 2021 | |||
| Acceleron XLRN Q1 2021 |
Acceleron XLRN Q2 2021 |
||
| May 6, 2021 | Aug. 5, 2021 | ||
| 2020 | |||
| Acceleron XLRN Q1 2020 |
Acceleron XLRN Q2 2020 |
Acceleron XLRN Q3 2020 |
Acceleron XLRN Q4 2020 |
| May 11, 2020 | Aug. 6, 2020 | Nov. 5, 2020 | Feb. 25, 2021 |
| 2019 | |||
| Acceleron XLRN Q1 2019 |
Acceleron XLRN Q2 2019 |
Acceleron XLRN Q3 2019 |
Acceleron XLRN Q4 2019 |
| May 9, 2019 | Aug. 5, 2019 | Nov. 6, 2019 | Feb. 27, 2020 |
2018 |
|||
| Acceleron XLRN Q4 2018 |
|||
May 8, 2018 |
Aug. 2, 2018 |
Oct. 30, 2018 |
Feb. 27, 2019 |
2017 |
|||
May 8, 2017 |
August 3, 2017 |
Nov. 7, 2017 |
Feb. 27, 2018 |
2016 |
|||
05/05/2016 |
08/04/2016 |
11/03/2016 |
03/01/2017 |
2015 |
|||
11/04/2015 |
02/25/2016 |
||
Acceleron: Luspatercept New Data Is A Buy Signal [June 7, 2018, Seeking Alpha]
Acceleron Pharma is a development stage biotechnology company.
but I did from 2015 to August 2021
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CLDX |
| CLSN |
| EPZM |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| IONS |
| ISRG |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SAGE |
| SGEN |
| SYRS |
| TTPH |
| VBLT |
| VSTM |
| XLRN |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2021 William P. Meyers